Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]      
Revenues $ 127,117 $ 90,291 $ 68,801
Cost of revenues [1] 30,187 17,698 12,311
Research and development [1] 31,118 24,299 18,014
Sales and marketing [1] 50,266 32,841 28,521
General and administrative [1] 39,144 20,641 8,103
Depreciation, amortization and impairment 6,143 661 730
Operating (loss) profit (29,741) (5,849) 1,122
Finance expenses (income), net (13,348) 4,386 734
(Loss) profit before taxes (16,393) (10,235) 388
Taxes on income 2,017 1,237 1,200
Net loss (18,410) (11,472) (812)
Accretion of preferred stock to redemption value 0 (77,063) (7,297)
Net loss attributable to common stockholders, basic (18,410) (88,535) (8,109)
Net loss attributable to common stockholders, diluted $ (18,410) $ (88,535) $ (8,109)
Net loss per stock attributable to common stockholders      
Net loss per stock attributable to common stockholders – basic (in dollars per share) [2] $ (0.14) $ (3.31) $ (0.51)
Net loss per stock attributable to common stockholders – diluted (in dollars per share) [2] $ (0.14) $ (3.31) $ (0.51)
Weighted Average Number of Shares Outstanding, Basic [Abstract]      
Weighted-average number of stocks used in computing net loss per stock attributable to common stockholders, basic (in shares) [2] 130,756,484 26,745,020 16,028,560
Weighted-average number of stocks used in computing net loss per stock attributable to common stockholders, diluted (in shares) [2] 130,756,484 26,745,020 16,028,560
[1] (1) Exclusive of depreciation, amortization and impairment presented separately.
[2] (2) Prior period results have been adjusted to reflect the exchange of Innovid Inc’s common stock for Innovid Corp’s common stock at an exchange ratio of approximately 1.337 because of the Transaction. See Note 3, Transaction for further details.